Literature DB >> 23442587

Additive preventive effect of influenza and pneumococcal vaccines in the elderly: results of a large cohort study.

Aba Mahamat1, Jean-Pierre Daurès, Benoît de Wzieres.   

Abstract

Elderly people are at increased risk of influenza and pneumococcal diseases. Influenza increases clinical pneumococcal disease incidence. Pneumococcal vaccination could therefore be a supplement to influenza vaccination. This study evaluated all-cause mortality and antibiotic consumption according to elderly people's influenza and pneumococcal vaccination status. Its goal was to demonstrate that vaccination with both Influenza and pneumococcal vaccines decrease all-cause mortality and antibiotic consumption. From 2004-10-01 to 2004-12-31 (3 mo), elderly people (≥ 65 y) who lived in the Gard department (South of France) were offered both vaccinations. Among the 68,897 subjects followed-up one year after this vaccination campaign, 21,303 (30.9%) were vaccinated with both vaccines, 18,651 (27.1%) with influenza vaccine alone, 3,769 (5.5%) with pneumococcal vaccine alone; 25,174 (36.5%) subjects were unvaccinated. Mortality rate (per 1,000 inhabitants-year) adjusted on gender, age and prior underlying chronic disease was 17.9 (95% CI: 16.3-19.6), 20.8 (19.0-22.8), 22.5 (19.0-26.6) and 24.7 (22.7-26.8), respectively. It was 42.1 (38.8-45.8) in elderly people with underlying chronic disease who received both vaccines vs. 58.1 (53.7-62.9) in unvaccinated elderly people. The decrease in mortality rate was 27.0% (20.0-34.0) in subjects who received both vaccines and 16.0% (6.0-24.0) in those who received influenza vaccine. No significant reduction in mortality rate was seen with the pneumococcal vaccine alone. Influenza and/or pneumococcal vaccinations did not decrease antibiotic consumption that drastically increases during the winter period. An additive effect was observed in the prevention of all-cause mortality with influenza and pneumococcal vaccines given together in elderly people, including in those with underlying chronic disease.

Entities:  

Keywords:  23-valent pneumococcal capsular polysaccharide vaccine; additive effect; cohort study; elderly; influenza vaccine; treatment outcome

Mesh:

Substances:

Year:  2013        PMID: 23442587      PMCID: PMC3667927          DOI: 10.4161/hv.22550

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  36 in total

1.  Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan--a representative population-based comparative study.

Authors:  Yu-Chia Chang; Yiing-Jenq Chou; Jen-Yin Liu; Te-Feng Yeh; Nicole Huang
Journal:  J Infect       Date:  2012-05-03       Impact factor: 6.072

2.  [Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions].

Authors:  J Gaillat; D Zmirou; M R Mallaret; D Rouhan; J P Bru; J P Stahl; P Delormas; M Micoud
Journal:  Rev Epidemiol Sante Publique       Date:  1985       Impact factor: 1.019

3.  The clinical effectiveness of pneumococcal vaccine in the elderly.

Authors:  R V Sims; W C Steinmann; J H McConville; L R King; W C Zwick; J S Schwartz
Journal:  Ann Intern Med       Date:  1988-05       Impact factor: 25.391

4.  The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease.

Authors:  K L Nichol; L Baken; J Wuorenma; A Nelson
Journal:  Arch Intern Med       Date:  1999-11-08

5.  Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study.

Authors:  M S Simberkoff; A P Cross; M Al-Ibrahim; A L Baltch; P J Geiseler; J Nadler; A S Richmond; R P Smith; G Schiffman; D S Shepard
Journal:  N Engl J Med       Date:  1986-11-20       Impact factor: 91.245

6.  Additive preventive effect of influenza and pneumococcal vaccines in elderly persons.

Authors:  B Christenson; J Hedlund; P Lundbergh; A Ortqvist
Journal:  Eur Respir J       Date:  2004-03       Impact factor: 16.671

7.  Clinical effectiveness of influenza vaccination in Manitoba.

Authors:  D S Fedson; A Wajda; J P Nicol; G W Hammond; D L Kaiser; L L Roos
Journal:  JAMA       Date:  1993-10-27       Impact factor: 56.272

8.  Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.

Authors:  J C Butler; R F Breiman; J F Campbell; H B Lipman; C V Broome; R R Facklam
Journal:  JAMA       Date:  1993-10-20       Impact factor: 56.272

Review 9.  Pneumococcal vaccination for the elderly in The Netherlands? Assessment of the quality and content of available comparative studies.

Authors:  W J J Assendelf; R J P M Scholten; M Offringa
Journal:  Neth J Med       Date:  2004-02       Impact factor: 1.422

10.  Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up.

Authors:  J Hedlund; B Christenson; P Lundbergh; A Ortqvist
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

View more
  11 in total

1.  [Pneumococcal vaccination for prevention of pneumonia].

Authors:  A Kwetkat; S Hagel; C Forstner; M W Pletz
Journal:  Z Gerontol Geriatr       Date:  2015-04-16       Impact factor: 1.281

2.  [Influenza: special aspects in old age].

Authors:  A Kwetkat; A Leischker; H J Heppner
Journal:  Z Gerontol Geriatr       Date:  2018-06-27       Impact factor: 1.281

3.  Double-Edged Role of Interleukin 17A in Streptococcus pneumoniae Pathogenesis During Influenza Virus Coinfection.

Authors:  Ganesh Ambigapathy; Taylor Schmit; Ram Kumar Mathur; Suba Nookala; Saad Bahri; Liise-Anne Pirofski; M Nadeem Khan
Journal:  J Infect Dis       Date:  2019-07-31       Impact factor: 5.226

Review 4.  [Vaccination in advanced age].

Authors:  H J Heppner; A Leischker; P Wutzler; A Kwetkat
Journal:  Internist (Berl)       Date:  2018-02       Impact factor: 0.743

5.  Pneumococcal vaccines: understanding centers for disease control and prevention recommendations.

Authors:  Mehdi Mirsaeidi; Dean E Schraufnagel
Journal:  Ann Am Thorac Soc       Date:  2014-07

Review 6.  Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance.

Authors:  Chiara Scelfo; Francesco Menzella; Matteo Fontana; Giulia Ghidoni; Carla Galeone; Nicola Cosimo Facciolongo
Journal:  Vaccines (Basel)       Date:  2021-04-22

Review 7.  The full benefits of adult pneumococcal vaccination: A systematic review.

Authors:  Elizabeth T Cafiero-Fonseca; Andrew Stawasz; Sydney T Johnson; Reiko Sato; David E Bloom
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

Review 8.  Effects of influenza vaccination on the risk of cardiovascular and respiratory diseases and all-cause mortality.

Authors:  Yangyang Cheng; Xinxi Cao; Zhi Cao; Chenjie Xu; Li Sun; Ying Gao; Yuan Wang; Shu Li; Cunjin Wu; Xin Li; Yaogang Wang; Sean X Leng
Journal:  Ageing Res Rev       Date:  2020-07-16       Impact factor: 10.895

Review 9.  Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association.

Authors:  Bin Cao; Yi Huang; Dan-Yang She; Qi-Jian Cheng; Hong Fan; Xin-Lun Tian; Jin-Fu Xu; Jing Zhang; Yu Chen; Ning Shen; Hui Wang; Mei Jiang; Xiang-Yan Zhang; Yi Shi; Bei He; Li-Xian He; You-Ning Liu; Jie-Ming Qu
Journal:  Clin Respir J       Date:  2017-09-26       Impact factor: 2.570

10.  Effect of vaccination on the use of antimicrobial agents: a systematic literature review.

Authors:  T Mark Doherty; William P Hausdorff; Karl G Kristinsson
Journal:  Ann Med       Date:  2020-06-29       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.